BioSpace News Archive

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.

PenRad offers a solution to reduce Radiologists’ liability and malpractice, without practice burden.

Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Tuesday, July 14th at 10:00 a.m. Eastern Time to review its neurology franchise.

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.

Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. The final data collection date is six months after the last patient in. “Tumor Treating Fields therapy has demonstrated efficacy in in vitr

- Positive CRV431 Data in Models of Acute Pulmonary Injury and SARS-CoV-2 Viral Replication - CRV431 attenuated lung inflammation and damage similar to or better than dexamethasone, including reductions in neutrophils and IL-6 CRV431 decreased SARS-CoV-2 replication and production of infectious virus in vitro CRV431 may offer opportunity to treat both viral infection and lung inflammation in COVID-19 EDISON, NJ / ACCESSWIRE / July 7, 2020 / Hepion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “Company”), a biotechnology company developing novel therapeutics for the treatment of unmet medical needs, today announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for trans sodium crocetinate (TSC) in COVID-19 patients

The Company also reports that all preferred shares and warrants outstanding have been exercised, establishing a cash balance of approximately $6 Million as of June 30, 2020

Oryzon Genomics, S.A. (MAD: ORY) (" Oryzon " or the " Company "), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, today announced that on June 25 th it agreed to sell 7,273,000 new common shares (the “ New Shares ”) at a price of 2.75 euros per share, representing a 10.7% discount from the closing price of June 24, for an aggregate amount of EUR 20 Million (the

Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced new top talent joining the Company’s Communications business.